期刊文献+

基质金属蛋白酶1/蛋白酶活性受体-1信号通路在胶质瘤发展中的作用 被引量:1

Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression or- human gliomas
原文传递
导出
摘要 目的探讨基质金属蛋白酶l/蛋白酶活性受体-l(MMP-1/PARl)信号通路在脑胶质瘤发展的作用及其意义。方法应用免疫组织化学方法检测108例原发性胶质瘤患者肿瘤组织中MMP.1和PARl的表达模式。采用Kaplan.Meier生存分析和Cox比例风险模型分析胶质瘤患者的预后。结果免疫染色结果显示108例患者活体组织有83.3%表达MMP-1(90/108),76.9%表达PARl(83/108)。PARl的表达与MMP.1的表达显著相关(r=0.8,P〈0.01)。高级别胶质瘤MMP-1和PARl的免疫组织化学(IHC)总分明显高于低级别胶质瘤(两者P〈0.01)。此外,MMP-1和PARl表达高的患者Krnofsky行为能力(KPS)评分低于MMP-1和PARl表达低的患者(两者P〈0.01)。而且,患者总体生存率降低的结果表明,MMP-1和PARl表达情况是胶质瘤的强预后指标(P〈0.01)。多因素Cox分析显示KPS(P〈0.01)、WHO病理分级(P〈0.01)、MMP-1(P〈0.01)和PARl(P〈0.01)是影响脑胶质瘤预后的独立因素。结论脑胶质瘤中MMP-1/PARl信号通路的活化与肿瘤恶性程度及临床结果相关。 Objective To investigate the effect of matrix metalloproteinase-1 (MMP-1) and pro- teinase-activated receptor-1 (PAR1) on the progression of human gliomas. Methods Immunohistochemi- cal staining was performed to detect the expression patterns of MMP-1 and PAR1 in biopsies from 108 pa- tients with primary gliomas. Kaplan-Meier survival and Cox regression analyses were done to evaluate the prognosis of patients. Results Immunostaining revealed MMP-1 to be expressed in 83.3% (90/108) and PAR1 in 76. 9% (83/108) of the biopsies respextively. PAR1 expression was significantly correlated with that of MMP-1 (r = 0. 8 ,P 〈 0. 01 ). The total immunohistochemistry (IHC) scores for MMP-1 and PAR1 were significantly higher in high-grade tumors than in low-grade tumors (both P 〈 0. 01 ). In addition, pa- tients with high MMP-1 and high PAR1 expression had lower Karnofsky performance scale (KPS) scores than those with low MMP-1 and low PAR1 expression (both P 〈0. 01). Moreover, MMP-1 and PAR1 ex- pression was shown to be a strong prognostic marker for decreased overall survival (P 〈 O. 01, respective- ly). Furthermore, Cox multi-factor analysis showed that KPS ( P 〈 0. O1 ), WHO grade ( P 〈 O. O1 ), MMP-1 (P 〈0. O1 ), and PAR1 (P 〈0.01 ) were independent prognostic factors for human gliomas. Con- clusion Our results suggest that in gliomas, the upregulation of MMP-1 and PAR1 correlates with histo- logical malignancy ~rade and clinical outcome.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2012年第2期247-249,共3页 Chinese Journal of Experimental Surgery
关键词 胶质瘤 基质金属蛋白酶 蛋白酶活性受体 预后 Gliomas Matrix metalloproteinase Proteinase-activated receptor Prognosis
  • 相关文献

参考文献7

  • 1Pei D. Matrix metalloproteinases target protease-aetivated receptors on the tumor cell surface. Cancer Cell,2005,7:207-208.
  • 2汤坚强,万远廉,刘玉村,戎龙,汪欣,朱静.反义组织因子cDNA转染对LoVo细胞基质金属蛋白酶-7及其抑制物-1表达的影响[J].中华实验外科杂志,2006,23(10):1226-1227. 被引量:4
  • 3Boire A, Covie L, Agarwal A, et al. PAR1 is a matrix metaUoprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell,2005,120 : 303 -313.
  • 4Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor ( PAR-1 ) in human melanoma. Oncogene ,2003,22:3130-3137.
  • 5Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res, 2009,69 : 6223 -6231.
  • 6马玉亮,时德.基质金属蛋白酶与下肢静脉曲张血管重塑的关系研究进展[J].中华实验外科杂志,2004,21(1):119-120. 被引量:7
  • 7Junge CE, Lee C J, Hubbard KB, et al. Protease-activated receptor-1 in human brain:localization and functional expression in astrocytes. Exp Neurol,2004,188:94-103.

二级参考文献5

共引文献9

同被引文献2

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部